 CAMBRIDGE, Mass., Aug. 26, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegdes arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2 in an advisory capacity. 